Twist Bioscience (TWST) to Release Earnings on Monday

Key Points

• Twist Bioscience (TWST) is set to release its Q3 2025 earnings results on August 4th, with analysts expecting an earnings per share (EPS) of ($0.54) and revenue of $95.52 million.
• The company reported a loss of ($0.66) EPS in its previous earnings announcement on May 5th, missing estimates, but surpassed revenue expectations with $92.79 million.
• Recent insider sales include COO Patrick John Finn and SVP Paula Green, indicating a 1.05% and 0.84% decrease in their respective share positions.

Twist Bioscience (NASDAQ:TWST - Get Free Report) is expected to post its Q3 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect Twist Bioscience to post earnings of ($0.54) per share and revenue of $95.52 million for the quarter. Twist Bioscience has set its Q3 2025 guidance at EPS and its FY 2025 guidance at EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Trading Up 2.6%

Shares of Twist Bioscience stock opened at $35.99 on Monday. The stock has a market capitalization of $2.16 billion, a P/E ratio of -11.07 and a beta of 2.41. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $34.13 and a 200 day simple moving average of $39.04. Twist Bioscience has a 12-month low of $27.12 and a 12-month high of $60.90.

Insider Buying and Selling

In related news, COO Patrick John Finn sold 2,800 shares of Twist Bioscience stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $105,420.00. Following the transaction, the chief operating officer owned 262,660 shares of the company's stock, valued at $9,889,149. This trade represents a 1.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Paula Green sold 1,101 shares of Twist Bioscience stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the transaction, the senior vice president directly owned 129,380 shares in the company, valued at $4,871,157. The trade was a 0.84% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,903 shares of company stock worth $794,706. 3.01% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock worth $2,765,000 after acquiring an additional 3,181 shares during the last quarter. Royal Bank of Canada boosted its stake in Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock worth $1,585,000 after acquiring an additional 4,254 shares during the last quarter. Intech Investment Management LLC boosted its stake in Twist Bioscience by 18.9% during the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock worth $36,629,000 after acquiring an additional 37,577 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird decreased their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.